We are live on ! Find out more
ORKA icon

Oruka Therapeutics
ORKA

10 hedge funds and large institutions have $873K invested in Oruka Therapeutics in 2013 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.51% less ownership

Funds ownership: 6.12% → 2.61% (-3.5%)

17% less funds holding

Funds holding: 12 → 10 (-2)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

59% less capital inflows, than outflows

Capital inflows: $525K | Capital outflows: $1.29M

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$208K
2
Renaissance Technologies
Renaissance Technologies
New York
+$108K
3
Deutsche Bank
Deutsche Bank
Germany
+$91.7K
4
Nomura Holdings
Nomura Holdings
Japan
+$41.7K
5
HighTower Advisors
HighTower Advisors
Illinois
+$37.5K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1.28M
2
Citigroup
Citigroup
New York
-$6K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$5K
4
UBS
UBS
Switzerland
-$2.08K

ORKA Hedge Fund Activity: Q3 2013 in Review

10 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2013, worth a combined $873K — down 47% from $1.66M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ORKA and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $208K. The largest seller was Sabby Management, exiting entirely with an estimated $1.28M sold.

  • 10 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2013, down from 12 in Q2 2013.
  • Funds reported $873K of Oruka Therapeutics stock for Q3 2013, down 47% quarter-over-quarter.
  • 3 funds opened new Oruka Therapeutics positions in Q3 2013 and 4 closed out, a net change of -1 holder.
  • The largest Oruka Therapeutics buyer in Q3 2013 was Vanguard Group, an estimated $208K added.
  • The largest Oruka Therapeutics seller in Q3 2013 was Sabby Management, an estimated $1.28M sold.

Based on aggregated 13F filings for Q3 2013.